Velká Británie - angličtina - VMD (Veterinary Medicines Directorate)

forte healthcare ltd - fluoxetine - tablet - neurological agent behavioural - dogs

Velká Británie - angličtina - VMD (Veterinary Medicines Directorate)

forte healthcare ltd - fluoxetine - tablet - neurological agent behavioural - dogs

Malajsie - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

servier malaysia sdn bhd - perindopril salified with tert-butylamin -

Singapur - angličtina - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - peginterferon alfa-2a - injection - 135 mcg/0.5 ml - peginterferon alfa-2a 135 mcg/0.5 ml

Singapur - angličtina - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - peginterferon alfa-2a - injection - 180 mcg/0.5 ml - peginterferon alfa-2a 180 mcg/0.5 ml

Evropská unie - angličtina - EMA (European Medicines Agency)

schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b: treatment of adult patients with chronic hepatitis b associated with evidence of hepatitis b viral replication (presence of hbv-dna and hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and/or fibrosis.chronic hepatitis c:adult patients:introna is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv (see section 4.4).the best way to use introna in this indication is in combination with ribavirin.chidren and adolescents:introna is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for serum hcv-rna. the decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, hcv genotype and viral load. the expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f.hoffmann-la roche ltd. - peginterferon alfa-2a - solution for injection - 180mcg/0,5ml

Singapur - angličtina - HSA (Health Sciences Authority)

roche singapore pte. ltd. - ribavirin - tablet, film coated - 200 mg - ribavirin 200 mg

Singapur - angličtina - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - ribavirin - capsule - 200 mg - ribavirin 200 mg

Singapur - angličtina - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - moxifloxacin hcl eqv moxifloxacin - tablet, film coated - 400 mg - moxifloxacin hcl eqv moxifloxacin 400 mg